KLRS
Kalaris Therapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$3.90
−1.02%Aug 11, 2026, 00:00 UTC
Kalaris Therapeutics, Inc. reported a net loss of $11.5 million for Q2 2026, with diluted loss per share of $0.48, and held $93.5 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
Aug 4, 2026, 06:22 UTC
Kalaris Therapeutics Inc.'s stock price rose 15.4% during mid-day trading on Monday, trading as high as $4.09 and last at $4.05, with volume of 155,903 shares.
Source: